Reducing Cost within Advanced Therapy Clinical Trials
The challenge for advanced therapy companies is that they need to develop a supply chain that delivers their therapy, at scale, without adding significantly to the cost of goods sold (COGS). In this case study we’ll demonstrate how a company saw 55% cost savings across its distribution system, and increased visibility of its supply chain through meaningful data. By trusting our team of experts to deliver a robust global storage and logistics strategy, the clinical trial ran more efficiently and provided the Sponsor company with the confidence to focus on other high value activities.
Topic: Cold-Chain Logistics, Topic: Cell Therapy S..........
Supporting our Troops - Transporting the AFMES DNA Repository to Dover Air Force Base
In observance of the upcoming Veterans Day holiday on November 11, we'd like to share a case study on how the Fisher BioServices team actively supports our troops and share our appreciation for all that they do. Together with our parent company, Thermo Fisher Scientific, we work with veterans to make the world a healthier place.
Topic: Biobanking and Biorepository, Topic: Cold-C..........
Cooling Valley Fever: Unique Kits for a Unique Clinical Trial
Fisher BioServices supports clinical trials in numerous ways, including acquiring and distributing clinical agents and the design and assembly of biospecimen collection kits. Recently, the staff members at the Clinical Agent and Specimen Repository (CASR), which Fisher BioServices operates for the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH), were challenged to support a particularly unique clinical trial: The efficacy of fluconazole in the treatment of Valley Fever.
Content: Case Study, Topic: Kit Production
Developing Ebola Vaccine and Securing Your Cold Chain Logistics Plan
Recent reports issued by the Centers for Disease Control and Prevention (CDC) show that efforts to contain the Ebola outbreak are yielding results. And even as we applaud the news, and also understand the need to continue the current efforts at an intense level, our collective attention is turning to the next step: developing a vaccine to prevent another outbreak.
Topic: Cold-Chain Logistics, Topic: GMP Biologics ..........